12 former FDA officials criticize statements made by current vaccine chief

Twelve previous leaders of the U.S. Food and Drug Administration, appointed by both Republican and Democratic administrations, have sharply criticized recent claims by the agency's current vaccine chief that cast doubt on vaccine safety. The former officials warned that the FDAs proposed changes to handling vaccines for influenza, COVID-19, and other respiratory illnesses, outlined in an internal memo last week, could harm the very populations the agency is meant to protect, including millions of high-risk Americans.

These proposed directives are not minor tweaks or ordinary policy updates. They mark a significant shift in the FDAs understanding of its mission, wrote the former commissioners and acting commissioners in The New England Journal of Medicine on Wednesday.

The internal memo, authored by Dr. Vinay Prasad, the FDA vaccine chief, has not been publicly released. According to multiple sources, the memo claimed that a review identified at least ten children who died after receiving COVID-19 vaccinations, suggesting myocarditis as a potential cause. However, Prasad did not provide supporting data such as the childrens ages, preexisting conditions, or the method used to link the deaths to vaccination. These findings were also not published in a peer-reviewed journal.

Prasads memo reportedly proposed changes to how the FDA manages flu shots and the simultaneous administration of multiple vaccines. While some vaccine skeptics argue that multiple doses might overwhelm a childs immune system or that ingredients could accumulate to cause harm, scientific studies consistently find no evidence supporting these concerns.

The former FDA leaders emphasized that the claim of child deaths linked to COVID-19 vaccines relied on a surveillance system that lacks detailed medical records, and prior analyses of such reports by government scientists reached different conclusions. They highlighted substantial evidence showing that COVID-19 vaccines significantly reduce severe illness and hospitalization in children.

The memo incorrectly states that 'we do not have reliable data' on the benefits of COVID vaccination in children, the former officials noted. Open debate on recommendations for children at lower risk is valid, but robust evidence demonstrates that vaccination lowers the risk of severe disease and hospitalization for many children and adolescents.

The former leaders also warned that the proposed changes could undermine established scientific methods for updating vaccines, slow innovation in developing improved vaccines, and reduce transparency for the public.

A Department of Health and Human Services spokesperson responded by saying that criticisms from former FDA officials who opposed higher standards for vaccine evaluation indicate that current efforts are on the right track.

Medical professionals have voiced concern about the memo. Dr. Ronald Nahass, president of the Infectious Diseases Society of America, said, Vaccines save lives. It is concerning when the FDA spreads confusion and mistrust without evidence, making lifesaving vaccines harder to access and increasing public uncertainty.

The FDAs planned changes arrive amid broader federal shifts in vaccine policy led by Health Secretary Robert F. Kennedy Jr., who has previously removed advisory committees and personnel over disagreements regarding vaccine recommendations. The CDCs vaccine advisory panel is scheduled to meet later this week to discuss hepatitis B immunization for newborns and other vaccination topics.

Analysis: FDA Vaccine Policy Controversy

The recent criticism from twelve former FDA leaders underscores a growing divide over the agency's handling of vaccine safety. Their joint statement emphasizes that the proposed changes, outlined in Dr. Vinay Prasad's internal memo, could negatively impact public health, particularly high-risk populations such as children and the elderly.

The memo's claims linking COVID-19 vaccines to child fatalities lack publicly available data and peer-reviewed validation. Experts note that the surveillance system referenced does not provide sufficient medical detail to establish causality, and existing evidence strongly supports the protective benefits of vaccination against severe illness.

Proposed changes to influenza and multi-dose vaccine management raise concerns about undermining established scientific processes, slowing innovation, and reducing transparency. Health officials defending the memo frame the criticism as resistance to higher standards, while medical professionals stress that unverified claims may erode public trust in lifesaving vaccines.

As federal vaccine policy undergoes shifts under Health Secretary Robert F. Kennedy Jr., the upcoming CDC advisory panel meeting will be a critical point to observe how these internal debates influence official guidance on childhood immunizations and broader public health strategies.

Sources:

• 12 ex-FDA leaders criticize claims made by agency's current vaccine chief